Brusatol induces ferroptosis to inhibit hepatocellular carcinoma progression by targeting ATF3
Chemical Biology and Drug Design
JUNE 11, 2024
Using RNA-seq and through in vitro and in vivo studies, we determined that brusatol suppresses hepatocellular carcinoma progression by inducing ATF3-mediated ferroptosis. Therefore, our research revealed the biological effect of brusatol treatment and provided ATF3 as a novel therapeutic target and prognostic biomarker for HCC therapy.
Let's personalize your content